Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Investigational New Drugs

Volumn 34, Issue 3, 2016, Pages 290-299

  Shah, Manisha H ^a   Lorigan, Paul ^b   O’Brien, Mary E R ^c   Fossella, Frank V ^d   Moore, Kathleen N ^e   Bhatia, Shailender ^f   Kirby, Maurice ^g   Woll, Penella J ^h  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g IMMUNOGEN INC   (United States)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antibody drug conjugate; CD56; DM1; IMGN901; Lorvotuzumab mertansine

Indexed keywords

LORVOTUZUMAB MERTANSINE; CD56 ANTIGEN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; CARCINOID; CEREBRAL BLINDNESS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOSE LIMITING TOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ELIMINATION HALF-LIFE; EWING SARCOMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; LETHAL DOSE; LETHARGY; LEUKOENCEPHALOPATHY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MENINGITIS; MENTAL DISEASE; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; SARCOMA; SENSORY NEUROPATHY; SMALL CELL LUNG CANCER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VASCULAR DISEASE; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CD56 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960128802     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0336-9     Document Type: Article

References (30)

1. Zeromski J, Nyczak E, Dyszkiewicz W (2001) Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem Cytobiol 39(Suppl 2):36–37
2. NCAM1 neural cell adhesion molecule 1 (2015) www.ncbi.nlm.nih.gov/gene/4684. Accessed 23 Dec 2015
3. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, et al. (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236:799–806
4. Griffin JD, Hercend T, Beveridge R, Schlossman SF (1983) Characterization of an antigen expressed by human natural killer cells. J Immunol 130:2947–2951
5. Patel K, Moore SE, Dickson G, Rossell RJ, Beverley PC, et al. (1989) Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer 44:573–578
6. Kurokawa M, Nabeshima K, Akiyama Y, Maeda S, Nishida T, et al. (2003) CD56: a useful marker for diagnosing Merkel cell carcinoma. J Dermatol Sci 31:219–224
7. Ohishi Y, Kaku T, Oya M, Kobayashi H, Wake N, et al. (2007) CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol Oncol 107:30–38
8. Guo W, Xing C, Dong A, Lin X, Lin Y, et al. (2013) Numbers and cytotoxicities of CD3 + CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol Ther 14:916–921
9. McNiff JM, Cowper SE, Lazova R, Subtil A, Glusac EJ (2005) CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both? J Cutan Pathol 32:541–545
10. Lantuejoul S, Moro D, Michalides RJ, Brambilla C, Brambilla E (1998) Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 22:1267–1276
11. Erovic I, Erovic BM (2013) Merkel cell carcinoma: the past, the present, and the future. J Skin Cancer 2013:929364
12. Asai N, Ohkuni Y, Kaneko N, Yamaguchi E, Kubo A (2014) Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 6:69–82
13. Lambert JM, O’Leary J, Whiteman KR, Goldmacher VS (2012) Targeting CD56 (NCAM)-expressing neoplasms with lorvotuzumab mertansine. In: Phillips GL (ed) Antibody-drug conjugates and immunoglobulins: from pre-clinical development to therapeutic applications. Springer, New York, pp. 273–296
14. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, et al. (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12:6064–6072
15. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, et al. (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 52:127–131
16. Erickson HK, Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14:799–805
17. Ballantyne A, Dhillon S (2013) Trastuzumab emtansine: first global approval. Drugs 73:755–765
18. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, et al. (2014) Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs 6:556–566
19. Fossella F, McCann J, Tolcher A, Xie H, Hwang LL et al (2005) Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. J Clin Oncol 23 (suppl; abstr 7159)
20. Fossella F, Woll P, Lorigan P, Tolcher A, O’Brien M, et al. (2009) Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). J Thorac Oncol 4(Suppl):S465
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
22. Wilson C, Leaning D, Shankland K, Langheinrich T, Battya R, et al. (2010) Cortical blindness as an unusual adverse drug reaction. J Med Cases 1:47–50
23. Woll PJ, O’Brien M, Fossella F, Shah SA, Clinch Y et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol 21 (suppl; abstr 536P)
24. Tolcher A, Forouzesh B, McCreery H, Hammond L, Patnaik A, et al. (2002) A phase I and pharmacokinetic study of BB-10901, a maytansinoid immunoconjugate, in CD56 expressing tumors. Eur J Cancer 38(Suppl 7):S152–S153
25. Soult MC, Feliberti EC, Silverberg ML, Perry RR (2012) Merkel cell carcinoma: high recurrence rate despite aggressive treatment. J Surg Res 177:75–80
26. Mojica P, Smith D, Ellenhorn JD (2007) Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 25:1043–1047
27. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, et al. (2014) Merkel cell carcinoma: epidemiology, Target, and therapy. Curr Dermatol Rep 3:46–53
28. Schlaak M, Podewski T, Von Bartenwerffer W, Kreuzberg N, Bangard C, et al. (2012) Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma. Eur J Dermatol 22:187–191
29. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114–2122
30. Jain N, Lam YM, Pym J, Campling BG (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77:1797–1808